Abstract

Next-Gen Sequencing Oligos (NGSO) can provide a comprehensive understanding of the therapeutic oligos' mechanism of action, optimize their design, and aid in their preclinical and clinical evaluation, ultimately leading to the development of safer and more effective therapeutic oligos. It is however critical to ensure good quality production of the NGSO adapter sequences. With insufficient adapter sequence qualities, we risk cross contamination and/or adapter dimer formation. A source of the challenge lies in the high-throughput nature of oligonucleotide manufacturing. Merck’s custom Next-Gen Sequencing Oligos (NGSO) are manufactured under rigorous conditions to ensure suitable purity and low cross contamination to meet research, commercial, and molecular diagnostic needs by eliminating adapter-quality-at-fault failed sequencing runs. Customer testing has revealed that NGSO-Gold delivers low adapter dimer formation (6.28%) as well as low cross contamination (no higher than 0.047% with a low of 0.015%).